Novartis, Teva End Long-Running Lotrel Patent Suit

Law360, New York (July 21, 2011, 4:14 PM EDT) -- Novartis Corp. and Teva Pharmaceuticals USA Inc. buried the hatchet Wednesday in a seven-year-old patent dispute in New Jersey over hypertension drug Lotrel, with a federal judge approving a settlement.

U.S. District Judge Garrett E. Brown Jr. signed off on the agreement, which resolves the case over Teva's generic version of Novartis' Lotrel. The parties settled two separate cases, each of which involve the same patent but different dosage strengths.

"Under the agreement, Teva admits to the validity of the Novartis patents and that they have...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.